Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study
Patients with end-stage kidney disease (ESKD) are at increased risk for SARS-CoV-2 infection and its complications compared with the general population. Several studies evaluated the effectiveness of COVID-19 vaccines in the dialysis population but showed mixed results. The aim of this study was to...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/1/49 |
| _version_ | 1797436606690361344 |
|---|---|
| author | Mohamad M. Alkadi Abdullah Hamad Hafedh Ghazouani Mostafa Elshirbeny Mohamed Y. Ali Tarek Ghonimi Rania Ibrahim Essa Abuhelaiqa Abdul Badi Abou-Samra Hassan Al-Malki Adeel A. Butt |
| author_facet | Mohamad M. Alkadi Abdullah Hamad Hafedh Ghazouani Mostafa Elshirbeny Mohamed Y. Ali Tarek Ghonimi Rania Ibrahim Essa Abuhelaiqa Abdul Badi Abou-Samra Hassan Al-Malki Adeel A. Butt |
| author_sort | Mohamad M. Alkadi |
| collection | DOAJ |
| description | Patients with end-stage kidney disease (ESKD) are at increased risk for SARS-CoV-2 infection and its complications compared with the general population. Several studies evaluated the effectiveness of COVID-19 vaccines in the dialysis population but showed mixed results. The aim of this study was to determine the effectiveness of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection in hemodialysis (HD) patients in the State of Qatar. We included all adult ESKD patients on chronic HD who had at least one SARS-CoV-2 PCR test done after the introduction of the COVID-19 mRNA vaccines on 24 December 2020. Vaccinated patients who were only tested before receiving any dose of their COVID-19 vaccine or within 14 days after receiving the first vaccine dose were excluded from the study. We used a test-negative case–control design to determine the effectiveness of the COVID-19 vaccination. Sixty-eight patients had positive SARS-CoV-2 PCR tests (cases), while 714 patients had negative tests (controls). Ninety-one percent of patients received the COVID-19 mRNA vaccine. Compared with the controls, the cases were more likely to be older (62 ± 14 vs. 57 ± 15, <i>p</i> = 0.02), on dialysis for more than one year (84% vs. 72%, <i>p</i> = 0.03), unvaccinated (46% vs. 5%, <i>p</i> < 0.0001), and symptomatic (54% vs. 21%, <i>p</i> < 0.0001). The effectiveness of receiving two doses of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection was 94.7% (95% CI: 89.9–97.2) in our HD population. The findings of this study support the importance of using the COVID-19 mRNA vaccine in chronic HD patients to prevent SARS-CoV-2 infection in such a high-risk population. |
| first_indexed | 2024-03-09T11:05:04Z |
| format | Article |
| id | doaj.art-5653cf1e7a4d4386951ea5bf95cc32a4 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T11:05:04Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-5653cf1e7a4d4386951ea5bf95cc32a42023-12-01T01:00:41ZengMDPI AGVaccines2076-393X2022-12-011114910.3390/vaccines11010049Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control StudyMohamad M. Alkadi0Abdullah Hamad1Hafedh Ghazouani2Mostafa Elshirbeny3Mohamed Y. Ali4Tarek Ghonimi5Rania Ibrahim6Essa Abuhelaiqa7Abdul Badi Abou-Samra8Hassan Al-Malki9Adeel A. Butt10Department of Medicine, Division of Nephrology, Hamad Medical Corporation, Doha P.O. Box 3050, QatarDepartment of Medicine, Division of Nephrology, Hamad Medical Corporation, Doha P.O. Box 3050, QatarDepartment of Quality and Patient Safety, Hamad Medical Corporation, Doha P.O. Box 3050, QatarDepartment of Medicine, Division of Nephrology, Hamad Medical Corporation, Doha P.O. Box 3050, QatarDepartment of Medicine, Division of Nephrology, Hamad Medical Corporation, Doha P.O. Box 3050, QatarDepartment of Medicine, Division of Nephrology, Hamad Medical Corporation, Doha P.O. Box 3050, QatarDepartment of Medicine, Division of Nephrology, Hamad Medical Corporation, Doha P.O. Box 3050, QatarDepartment of Medicine, Division of Nephrology, Hamad Medical Corporation, Doha P.O. Box 3050, QatarDepartment of Quality and Patient Safety, Hamad Medical Corporation, Doha P.O. Box 3050, QatarDepartment of Medicine, Division of Nephrology, Hamad Medical Corporation, Doha P.O. Box 3050, QatarDepartment of Quality and Patient Safety, Hamad Medical Corporation, Doha P.O. Box 3050, QatarPatients with end-stage kidney disease (ESKD) are at increased risk for SARS-CoV-2 infection and its complications compared with the general population. Several studies evaluated the effectiveness of COVID-19 vaccines in the dialysis population but showed mixed results. The aim of this study was to determine the effectiveness of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection in hemodialysis (HD) patients in the State of Qatar. We included all adult ESKD patients on chronic HD who had at least one SARS-CoV-2 PCR test done after the introduction of the COVID-19 mRNA vaccines on 24 December 2020. Vaccinated patients who were only tested before receiving any dose of their COVID-19 vaccine or within 14 days after receiving the first vaccine dose were excluded from the study. We used a test-negative case–control design to determine the effectiveness of the COVID-19 vaccination. Sixty-eight patients had positive SARS-CoV-2 PCR tests (cases), while 714 patients had negative tests (controls). Ninety-one percent of patients received the COVID-19 mRNA vaccine. Compared with the controls, the cases were more likely to be older (62 ± 14 vs. 57 ± 15, <i>p</i> = 0.02), on dialysis for more than one year (84% vs. 72%, <i>p</i> = 0.03), unvaccinated (46% vs. 5%, <i>p</i> < 0.0001), and symptomatic (54% vs. 21%, <i>p</i> < 0.0001). The effectiveness of receiving two doses of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection was 94.7% (95% CI: 89.9–97.2) in our HD population. The findings of this study support the importance of using the COVID-19 mRNA vaccine in chronic HD patients to prevent SARS-CoV-2 infection in such a high-risk population.https://www.mdpi.com/2076-393X/11/1/49COVID-19dialysisvaccine |
| spellingShingle | Mohamad M. Alkadi Abdullah Hamad Hafedh Ghazouani Mostafa Elshirbeny Mohamed Y. Ali Tarek Ghonimi Rania Ibrahim Essa Abuhelaiqa Abdul Badi Abou-Samra Hassan Al-Malki Adeel A. Butt Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study Vaccines COVID-19 dialysis vaccine |
| title | Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
| title_full | Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
| title_fullStr | Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
| title_full_unstemmed | Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
| title_short | Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
| title_sort | effectiveness of messenger rna vaccines against sars cov 2 infection in hemodialysis patients a case control study |
| topic | COVID-19 dialysis vaccine |
| url | https://www.mdpi.com/2076-393X/11/1/49 |
| work_keys_str_mv | AT mohamadmalkadi effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT abdullahhamad effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT hafedhghazouani effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT mostafaelshirbeny effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT mohamedyali effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT tarekghonimi effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT raniaibrahim effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT essaabuhelaiqa effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT abdulbadiabousamra effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT hassanalmalki effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT adeelabutt effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy |